drugset / Trial / NCT01265888
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
Timeline
- Start
- 2011-03
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitric Oxide | Other / unclassified | 5 ppm | Inhaled |
| Subject | Nitric Oxide | Other / unclassified | 15 ppm | Inhaled |
| Subject | Nitric Oxide | Other / unclassified | 20 ppm | Inhaled |